Physician profile
James C O'Brien
NPI 1417392325
$1,939.25
in general payments reported to CMS, 2019-2025
11 companies · $62.16 in 2025
The $62.16 reported for 2025 was less than what a typical Neuro-Ophthalmology provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $240 · 2021: $221 · 2022: $496 · 2023: $465 · 2025: $62.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $388.13 | 2021-2023 | Tepezza |
| Allergan, INC. | $298.81 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $296.21 | 2021-2023 | Xeomin |
| Abbvie INC. | $267.72 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $210.31 | 2019 | |
| Merz North America, INC. | $175.75 | 2019-2020 | |
| Alcon Vision LLC | $132.92 | 2019-2020 | |
| Amgen INC. | $62.16 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $52.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $35.36 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James O'Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.